Table 1 Baseline characteristics of SLE patients and the general population.
Variables | SLE patients (n = 8568) | General population (n = 34,272) | P |
|---|---|---|---|
Age, years | 41.24 ± 14.44 | 41.24 ± 14.44 | Matched |
Sex, female | 7527 (87.85) | 30,108 (87.85) | Matched |
Income | < 0.001 | ||
Quintile 1 | 2110 (24.63) | 5068 (14.79) | |
Quintile 2 | 1286 (15.01) | 5072 (14.80) | |
Quintile 3 | 1500 (17.51) | 5613 (16.38) | |
Quintile 4 | 1604 (18.72) | 7066 (20.62) | |
Quintile 5 | 1898 (22.15) | 10,547 (30.77) | |
Comorbidity | |||
Hypertension | 1124 (13.12) | 3097 (9.04) | < 0.001 |
Diabetes mellitus | 250 (2.92) | 1082 (3.16) | 0.2538 |
Hyperlipidemia | 630 (7.35) | 2196 (6.41) | 0.0016 |
Chronic kidney disease | 201 (2.35) | 84 (0.25) | < 0.001 |
Antiphospholipid antibody syndrome | 60 (0.70) | 1 (0.00) | < 0.001 |
Charlson comorbidity index | 2.28 ± 1.41 | 0.63 ± 1.05 | < 0.001 |
Medication* | |||
NSAIDs | 5000 (58.36) | 12,838 (37.46) | < 0.001 |
Glucocorticoids | 6777 (79.10) | 5977 (17.44) | < 0.001 |
Hydroxychloroquine | 6115 (71.37) | 52 (0.15) | < 0.001 |
Immunosuppressive agent | 2785 (32.50) | 113 (0.33) | < 0.001 |
ACE/ARB | 1294 (15.1) | 1937 (5.65) | |
Anti-platelet agent | 770 (8.99) | 867 (2.53) | < 0.001 |
Beta blocker | 547 (6.38) | 695 (2.03) | < 0.001 |
Calcium channel blocker | 1153 (13.46) | 1773 (5.17) | < 0.00 |
Cholesterol-lowering agent | 840 (9.80) | 1766 (5.15) | < 0.001 |
